Email Sign-Up
 
63 results found
Filter Filters icon
Apply

Article

Margetuximab

Margetuximab (Margenza) is a medicine approved by the Food and Drug Administration to be given with chemotherapy to treat metastatic, HER2-positive breast cancer after treatment with at least two ...

Article

Lapatinib

Lapatinib (Tykerb) is targeted therapy in the dual tyrosine kinase inhibitor class. It is used with the chemotherapy pill capecitabine (Xeloda) or the aromatase inhibitor letrozole (Femara) to ...

Article

Alpelisib

Alpelisib (Piqray) is a targeted therapy approved by the U.S. Food and Drug Administration to treat people with advanced or metastatic, hormone receptor-positive breast cancer that has tested ...

Article

Targeted therapy for triple-negative breast cancer

Learn more about the different classes of targeted therapies for triple-negative breast cancer, the tumor biomarkers that tell us who may benefit from them, and how they work.

Article

Targeted therapy for HER2-positive breast cancer

Article

Targeted therapy

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help the cells to grow. They look for a specific feature of a cancer cell, attach to it, ...

Story 06/06/22

Anti-HER2 drug trastuzumab deruxtecan found effective for HER2-low tumors

A study presented at the 2022 meeting of the American Society of Clinical Oncology of trastuzumab deruxtecan or TDX-d (Enhertu) is very likely to change the standard of care for many people with ...

Story 06/05/22

Palbociclib does not improve overall survival for metastatic breast cancer

The CDK 4/6 inhibitor palbociclib (Ibrance) did not extend overall survival when combined with hormonal therapy as a first-line treatment in people with hormone-receptor positive, HER2-negative ...

Story 12/14/21

Olaparib well tolerated in people with early-stage BRCA+, HER2- disease

Early results of a quality-of-life study presented at the 2021 San Antonio Breast Cancer Symposium found that olaparib did not worsen or prolong side effects when given after chemotherapy for ...

Story 12/10/21

T-DXd emerges as new standard second-line treatment for HER2+ MBC

Research presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) identified a new standard second-line treatment for metastatic disease, a more effective tyrosine kinase inhibitor, and ...